Palomar Labs (formerly Negev Labs) launched its first portfolio company, Ariadne Bio, via a spinout designed around candidates with prior human validation. The company’s lead program, AB-300, is a non-hallucinogenic serotonin 2A receptor agonist in development for Parkinson’s disease apathy, aiming to address the lack of approved motivation-focused therapies for this non-motor symptom.